Literature DB >> 30101160

Data for vancomycin elution, activity and impact on mechanical properties when incorporated into orthopedic bone cement.

Aaron R Bishop1, Sunjung Kim2, Matthew Squire3, Warren E Rose4,3, Heidi-Lynn Ploeg1,2,3.   

Abstract

In this article, we report data on the antibiotic elution and efficacy, and mechanical properties of Palacos bone cement with different amounts of added vancomycin (0.0, 0.125, 0.25, 0.5, 1.0, 2.0 g), see "Vancomycin elution, activity and impact on mechanical properties when added to orthopedic bone cement" (Bishop et al., 2018) [1]. Mechanical testing was performed for four-point bending, compression, and fracture toughness. The release characteristics of vancomycin was recorded for up to 60 days to estimate the elution profile. The eluted vancomycin efficacy at eliminating the four most common causative orthopedic implant pathogens is also reported.

Entities:  

Year:  2018        PMID: 30101160      PMCID: PMC6083008          DOI: 10.1016/j.dib.2018.07.028

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Value of the data These data are of value in cemented joint arthroplasty using Palacos with added vancomycin as a prophylactic measure against infection. The mechanical test data of wet cured samples demonstrated that mechanical properties of Palacos bone cement with upto 0.5 g of vancomycin met all ISO minimum requirements. The release characteristic test data showed that the elution profile is suited for clinical use since the maximum elution occurs during the critical first week after surgery and would effectively eliminate S. aureus contamination that may inadvertently occur during the surgical procedure. The antimicrobial activity test data showed that the eluted concentration from samples with greater than 0.25 g vancomycin per Palacos packet was sufficient to eliminate a 103 colony forming unit per mL (CFU/mL) initial inoculum of S. aureus, including methicillin-resistant S. aureus (MRSA).

Data

The data provided here are Mechanical test data: flexural modulus, flexural strength, compressive modulus, compressive yield strength, and fracture toughness calculated from the force-displacement curves. Scanning electron microscope (SEM) images from the fracture surfaces of four-point bending samples. Release characteristic test data for vancomycin added to Palacos bone cement. Antimicrobial activity test data for eluted vancomycin efficacy at eliminating four most common causative orthopedic implant pathogens (MRSA n315, ATTC MRSA 33591, ATCC S.aureus 29213, and ATCC S. epidermidis 35984).

Mechanical testing data

See Table 1, Table 2, Table 3.
Table 1

Results from four-point bend testing. Results are reported as median ± 1 standard deviation.

4 - Point bending test
CementAntibioticAmount of antibiotic added [g]MixingConditioningTesting conditionBending modulus [MPa]Bending strength [MPa]
PalacosVacuumAmbient, saline, 21 daysAmbient2192 ± 164.2155.40 ± 3.5313
PalacosVancomycin0.125VacuumAmbient, saline, 21 daysAmbient2349 ± 163.9157.72 ± 1.5153
PalacosVancomycin0.25VacuumAmbient, saline, 21 daysAmbient2357 ± 301.0152.63 ± 2.2213
PalacosVancomycin0.50VacuumAmbient, saline, 21 daysAmbient2267 ± 200.4156.71 ± 2.3313
PalacosVancomycin1.0VacuumAmbient, saline, 21 daysAmbient2369 ± 64.00155.80 ± 1.5413
PalacosVancomycin2.0VacuumAmbient, saline, 21 daysAmbient2038 ± 164.21,246.80 ± 1.7004

Significantly higher than the ISO minimum requirement of 1800 MPa.

Significantly lower than control׳s bending modulus.

Significantly higher than the ISO minimum requirement of 50 MPa.

Significantly lower than control׳s bending strength.

Table 2

Results from compression testing. Results are reported as median ± 1 standard deviation.

Compressive test
CementAntibioticAmount of antibiotic added [g]MixingConditioningTesting conditionCompressive modulus [MPa]Compressive yield strength [MPa]
PalacosVacuumAmbient, saline, 21 daysAmbient1559 ± 207.482.71 ± 63.522
PalacosVancomycin0.125VacuumAmbient, saline, 21 daysAmbient1543 ± 246.778.61 ± 47.912,3
PalacosVancomycin0.25VacuumAmbient, saline, 21 daysAmbient1279 ± 230.1177.01 ± 47.922,3
PalacosVancomycin0.50VacuumAmbient, saline, 21 daysAmbient1282 ± 301.2173.12 ± 33.342,3
PalacosVancomycin1.0VacuumAmbient, saline, 21 daysAmbient1098 ± 182.9169.62 ± 25.443
PalacosVancomycin2.0VacuumAmbient, saline, 21 daysAmbient980.7 ± 230.4161.72 ± 11.543

Significantly lower than control׳s compressive modulus.

Significantly higher than the ISO minimum requirement of 70 MPa.

Significantly lower than control׳s compressive yield strength.

Table 3

Results from fracture toughness testing. Results are reported as median ± 1 standard deviation.

Fracture toughness test
CementAntibioticAmount of antibiotic added [g]MixingConditioningTesting conditionFracture toughness [MPa m1/2]
PalacosVacuumAmbient, saline, 21 daysAmbient2.685 ± 0.091
PalacosVancomycin0.125VacuumAmbient, saline, 21 daysAmbient2.627 ± 0.419
PalacosVancomycin0.25VacuumAmbient, saline, 21 daysAmbient2.428 ± 0.267
PalacosVancomycin0.50VacuumAmbient, saline, 21 daysAmbient2.467 ± 0.222
PalacosVancomycin1.0VacuumAmbient, saline, 21 daysAmbient2.465 ± 0.166
PalacosVancomycin2.0VacuumAmbient, saline, 21 daysAmbient2.187 ± 0.175
Results from four-point bend testing. Results are reported as median ± 1 standard deviation. Significantly higher than the ISO minimum requirement of 1800 MPa. Significantly lower than control׳s bending modulus. Significantly higher than the ISO minimum requirement of 50 MPa. Significantly lower than control׳s bending strength. Results from compression testing. Results are reported as median ± 1 standard deviation. Significantly lower than control׳s compressive modulus. Significantly higher than the ISO minimum requirement of 70 MPa. Significantly lower than control׳s compressive yield strength. Results from fracture toughness testing. Results are reported as median ± 1 standard deviation.

Drug elution data

See Table 4.
Table 4

Drug elution results over 60 days. Results (all units are mg) are reported as mean ± standard deviation (SD).

0.125 g
0.25 g
0.5 g
1.0 g
2.0 g
DaysMeanSDMeanSDMeanSDMeanSDMeanSD
00.0000.0000.0000.0000.0000.0000.0000.0000.0000.000
10.0060.0030.0100.0030.0220.0050.0520.0170.0480.011
20.0060.0000.0100.0000.0220.0000.0520.0000.0480.000
40.0200.0050.0170.0040.0410.0050.0790.0100.0700.006
80.0300.0050.0330.0010.0590.0020.1040.0070.0970.002
100.0300.0000.0330.0000.0590.0000.1040.0000.0970.000
150.0300.0000.0330.0000.0590.0000.1040.0000.0970.000
250.0300.0000.0330.0000.0590.0000.1050.0000.0980.000
450.0300.0000.0330.0000.0590.0000.1050.0000.0990.000
600.0310.0000.0330.0000.0590.0000.1050.0000.1000.000
Drug elution results over 60 days. Results (all units are mg) are reported as mean ± standard deviation (SD).

Antimicrobial activity testing

See Table 5, Table 6.
Table 5

Antimicrobial activity of eluted vancomycin (0.5 g) for three S. aureus strains. Results (all units are ) (colony forming units, CFU) are reported as mean ± 1 standard deviation (SD).

ATCC 29213
n315
ATCC 33591
DaysMeanSDMeanSDMeanSD
03.0700.1503.1500.0103.1500.050
11.6200.3201.0000.0001.0000.000
21.0000.0001.0000.0001.0000.000
31.0000.0001.0000.0001.0000.000
41.0000.0001.0000.0001.0000.000
51.0000.0001.0000.0001.0000.000
61.0000.0001.0000.0001.0000.000
71.0000.0001.0000.0001.0000.000
151.0000.0001.0000.0001.0000.000
Table 6

Antimicrobial activity of eluted vancomycin (0.125–2.0 g) for S.epidermidis 35984. Results (all units are ) are reported as mean ± 1 standard deviation (SD).

0.125 g
0.25 g
0.5 g
1.0 g
2.0 g
DaysMeanSDMeanSDMeanSDMeanSDMeanSD
03.0900.0403.0900.0403.0900.0403.0900.0403.0900.040
14.5001.0002.6102.3301.7001.7001.0001.0004.3200.290
25.0400.7904.0000.8703.6803.2302.5402.4103.5203.060
34.9001.0404.4001.2503.3800.1504.0401.0202.3102.010
45.2500.3505.2700.1405.0400.1904.6700.1604.5500.280
55.5001.0005.5001.0005.5001.0005.5001.0005.5001.000
65.5001.0004.3201.1403.8101.2402.8202.6401.9401.680
75.5001.0005.3300.1504.9400.5304.3601.5901.3702.380
155.5001.0005.5001.0001.8303.1800.6101.0501.0001.000
Antimicrobial activity of eluted vancomycin (0.5 g) for three S. aureus strains. Results (all units are ) (colony forming units, CFU) are reported as mean ± 1 standard deviation (SD). Antimicrobial activity of eluted vancomycin (0.125–2.0 g) for S.epidermidis 35984. Results (all units are ) are reported as mean ± 1 standard deviation (SD).

Experimental design, materials, and methods

Sample preparation

Cement, stored at 22 °C ± 1 °C, was prepared [2] with vacuum, − 50 to 100 mbar (Zimmer Compact Vacuum Cement Mixing System®). The six experimental groups were: control (Palacos® R Cement), and five treatments with 0.125 g, 0.25 g, 0.50 g, 1.0 g, and 2.0 g of vancomycin powder added to the polymer powder. Six samples per test were molded: drug elution disks (6 mm diameter × 4.5 mm height), compression cylinders (6 mm diameter × 12 mm height), four-point bend beams (75 mm × 10 mm × 3.3 mm), and fracture toughness beams (44 mm × 10 mm × 5 mm with crack length between 4.5 mm and 5.5 mm and width of 0.37 mm, Buehler® IsoMet™).

Mechanical testing

After 21 days in 1x PBS at 22 °C, mechanical testing was performed (Criterion C43.104, MTS Systems) according to ISO 5388 with force and displacement data recorded at 100 Hz. Displacement rate was 5 mm/min for four-point bending and compression tests and 10 mm/min for fracture toughness tests.

Release characteristic testing

Five cement disks per group, were submerged in 5 mL PBS in an incubator shaker at 37 °C and 100 rpm. At 1, 2, 4, 8, 10, 15, 25 and 45, and 60 days, 1.5 mL of the PBS was aspirated off, stored at − 20 °C, and samples were submerged in 5 mL fresh PBS. Vancomycin content was measured (high performance liquid chromatography with a C18 column [3]) in triplicate. Ten microliters of the sample was developed isocratically with 50 mM potassium phosphate buffer (pH 6.8) and acetonitrile (17:3) at a flow rate of 0.5 mL/min. Absorbance was monitored at 210 nm with peak intensity correlated to concentrations [4]. Three cement disks per group were sterilized (ethylene oxide gas), submerged in 3.4 mL tryptic soy broth (TSB; Becton Dickenson) and inoculated with bacteria (1000 CFU/mL): Methicillin-resistant Staphylococcus aureus (MRSA) n315 with a vancomycin minimum inhibitory concentration (MIC) of 0.5–1 mg/L [5], ATCC MRSA 33591 (vancomycin MIC 2 mg/L), ATCC S. aureus 29213 (vancomycin MIC 0.5 mg/L), and ATCC S. epidermidis 35984 (vancomycin MIC 1 mg/L) [6]. MRSA n315 was also tested at 106 CFU/mL. TSB samples, taken at inoculation, daily for 7 days, and again at 14 days, were serially diluted (Mueller Hinton II agar plates, Sigma-Aldrich) for bacterial enumeration. Bacterial colonies were quantified after 18–24 hours incubation. All testing was performed in triplicate.
Subject areaBiomechanics, Pharmacy
More specific subject areaOrthopedic, Antimicrobial agent
Type of dataImage (X-ray, microscopy, etc.), figure, tabulated
How data was acquiredSEM (Zeiss-LEO,Oberkochen, Germany), MTS (Criterion C43.104, MTS Systems, Eden Prairie, MN), High performance Liquid Chromatography (HPLC)
Data formatAnalyzed data
Experimental factorsPalacos bone cement different amounts of added vancomycin: 0.0, 0.125, 0.25, 0.5, 1.0, 2.0 g
Experimental featuresMechanical testing using MTS machine measured flexural modulus flexural strength, compressive modulus, compressive yield strength, and fracture toughness, according to ISO 5833. The drug elution test was determined using high performance liquid chromatography (HPLC) with aC18column. Three cylindrical samples (6 mm diameter × 4.5 mm height) were sterilized by ethylene oxide gas and then submerged in 3.4 mL of tryptic soy broth inoculated with bacteria for each test condition for antimicrobial activity testing. Drug elution cements were stored in − 20 °C freezer and all mechanical testing cements were wet cured in a phosphate-buffer solution (PBS) for 21 days at room temperature (22 °C) before testing.
Data source locationDepartment of Mechanical Engineering and School of Pharmacy, University of Wisconsin Madison
Data accessibilityData is with this article.
Related research articleBishop A.R., Kim S., Squire M.W., Rose W.E., Ploeg H., Vancomycin elution, activity and impact on mechanical properties when added to orthopedic bone cement, Journal of Mechanical Behavior of Biomedical Materials S1751–6161(18)30459-4, https://doi.org/10.1016/j.jmbbm.2018.06.033[1]
  6 in total

1.  Whole genome sequencing of meticillin-resistant Staphylococcus aureus.

Authors:  M Kuroda; T Ohta; I Uchiyama; T Baba; H Yuzawa; I Kobayashi; L Cui; A Oguchi; K Aoki; Y Nagai; J Lian; T Ito; M Kanamori; H Matsumaru; A Maruyama; H Murakami; A Hosoyama; Y Mizutani-Ui; N K Takahashi; T Sawano; R Inoue; C Kaito; K Sekimizu; H Hirakawa; S Kuhara; S Goto; J Yabuzaki; M Kanehisa; A Yamashita; K Oshima; K Furuya; C Yoshino; T Shiba; M Hattori; N Ogasawara; H Hayashi; K Hiramatsu
Journal:  Lancet       Date:  2001-04-21       Impact factor: 79.321

2.  Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion.

Authors:  Andrew D Berti; Paul R Hutson; Lucas T Schulz; Aaron P Webb; Warren E Rose
Journal:  Am J Health Syst Pharm       Date:  2015-03-01       Impact factor: 2.637

3.  Mechanical, material, and antimicrobial properties of acrylic bone cement impregnated with silver nanoparticles.

Authors:  Josh Slane; Juan Vivanco; Warren Rose; Heidi-Lynn Ploeg; Matthew Squire
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2014-12-02       Impact factor: 7.328

4.  Diffusion of rifampin and vancomycin through a Staphylococcus epidermidis biofilm.

Authors:  W M Dunne; E O Mason; S L Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

5.  Vancomycin elution, activity and impact on mechanical properties when added to orthopedic bone cement.

Authors:  Aaron R Bishop; Sunjung Kim; Matthew W Squire; Warren E Rose; Heidi-Lynn Ploeg
Journal:  J Mech Behav Biomed Mater       Date:  2018-06-28

6.  Stability of Reconstituted Telavancin Drug Product in Frozen Intravenous Bags.

Authors:  Zhengtian Gu; Anissa Wong; Elvira Raquinio; Alice Nguyen
Journal:  Hosp Pharm       Date:  2015-07-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.